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Test-Retest Reliability and Minimal
Detectable Change Scores for the
Timed “Up & Go” Test, the Six-Minute
Walk Test, and Gait Speed in People
With Alzheimer Disease
Julie D. Ries, John L. Echternach, Leah Nof, Michelle Gagnon Blodgett
Background. With the increasing incidence of Alzheimer disease (AD), deter-
mining the validity and reliability of outcome measures for people with this disease
is necessary.
Objective. The goals of this study were to assess test-retest reliability of data for
the Timed “Up & Go” Test (TUG), the Six-Minute Walk Test (6MWT), and gait speed
and to calculate minimal detectable change (MDC) scores for each outcome measure.
Performance differences between groups with mild to moderate AD and moderately
severe to severe AD (as determined by the Functional Assessment Staging [FAST]
scale) were studied.
Design. This was a prospective, nonexperimental, descriptive methodological
study.
Methods. Background data collected for 51 people with AD included: use of an
assistive device, Mini-Mental Status Examination scores, and FAST scale scores. Each
participant engaged in 2 test sessions, separated by a 30- to 60-minute rest period,
which included 2 TUG trials, 1 6MWT trial, and 2 gait speed trials using a comput-
erized gait assessment system. A specific cuing protocol was followed to achieve
optimal performance during test sessions.
Results. Test-retest reliability values for the TUG, the 6MWT, and gait speed were
high for all participants together and for the mild to moderate AD and moderately
severe to severe AD groups separately (intraclass correlation coefficients .973);
however, individual variability of performance also was high. Calculated MDC scores
at the 90% confidence interval were: TUG4.09 seconds, 6MWT33.5 m (110 ft),
and gait speed9.4 cm/s. The 2 groups were significantly different in performance
of clinical tests, with the participants who were more cognitively impaired being
more physically and functionally impaired.
Limitations. A single researcher for data collection limited sample numbers and
prohibited blinding to dementia level.
Conclusions. The TUG, the 6MWT, and gait speed are reliable outcome measures
for use with people with AD, recognizing that individual variability of performance
is high. Minimal detectable change scores at the 90% confidence interval can be used
to assess change in performance over time and the impact of treatment.
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Alzheimer disease (AD) is themost common form of de-mentia in elderly people and
affects an estimated 5.2 million indi-
viduals in the United States.1 It is
estimated that 13% of people aged
65 years and older are diagnosed
with AD, and the incidence and prev-
alence increase considerably with
age.1 With the aging of the popula-
tion, physical therapists in geriatrics
will be treating an increasing num-
ber of people with AD. Given the
need to measure outcomes to assess
progress or decline in function, spe-
cific clinical tools should be tested
for reliability and validity with indi-
viduals with AD.
There are recent publications sup-
porting the physical and functional
benefits of exercise in the manage-
ment of AD.2,3 Identification of ap-
propriate and useful outcome mea-
sures for people with AD would
enhance the ability to assess the ef-
fectiveness of interventions in clini-
cal and research environments. Our
current understanding of the psycho-
metric properties of specific clinical
tests with this population is limited.
Methodological studies assessing the
reliability of clinical tools for people
with AD or dementia are scarce, but
not nonexistent.4–8 Given the ex-
tremely limited research available ex-
clusively with people with a diagno-
sis of AD, information gleaned from
research with individuals with other
types of dementia was included in
our review of the literature. Mixed
results from studies make it difficult
to know which outcome measures
will best serve physical therapists’
needs in monitoring change in per-
formance in individuals with AD.
Outcome measures that have been
studied for reliability with individu-
als with AD or dementia include: the
Timed “Up & Go” Test (TUG),4,5,8,9
the Six-Minute Walk Test (6MWT),4,6
and gait speed.4,5,10
Reliability measurements indicate
the degree to which scores of a clin-
ical test are free from measurement
errors,11 and although conceptually
straightforward, the application of
this notion can be complex.11,12 Re-
liability can be expressed as relative
reliability or as absolute reliability. If
a measurement has high relative re-
liability, this indicates that repeated
measurements will reveal consistent
positioning or ranking of individuals’
scores within a group.11 If a measure-
ment has high absolute reliability,
this indicates that, upon repeated
measurement, scores show little vari-
ability.11 Relative reliability is mea-
sured with correlation coefficients.
The intraclass correlation coefficient
(ICC) evaluates correlation based
upon variance estimates from analy-
sis of variance13; the more common
the variance between sets of mea-
surements, the higher the ICC.12 The
ICC is an appropriate statistic for ex-
amining test-retest reliability.13 As a
general guideline, an ICC above .75
is considered to demonstrate good
reliability; for clinical measures, it is
suggested that reliability should ex-
ceed .90 to ensure reasonable
validity.13
Excellent test-retest reliability does
not necessarily ensure that individu-
als’ repeated performance will be
consistent from test to test. Scores
may vary, given expected variability
of individual performance and mea-
surement error. A measure of abso-
lute variability provides useful infor-
mation to delineate the “expected”
changes from “true” changes in per-
formance. Statistically, absolute reli-
ability is determined by the standard
error of measurement (SEM), or the
standard deviation of the measure-
ment errors,11,13 and a clinically use-
ful mechanism for looking at abso-
lute reliability is the minimal
detectable change (MDC) score.14
Recent literature presenting TUG8,10
and gait speed10 data for individuals
with dementia highlights the impor-
tance of understanding relative ver-
sus absolute reliability. Even though
test-retest reliability coefficients for
clinical tests are high, individual vari-
ability and measurement error make
it very difficult to identify a “true”
change in performance over time.
Minimal detectable change scores
provide researchers and clinicians
with the opportunity to determine
whether a change in performance is
a meaningful change (ie, beyond ex-
pected measurement error and indi-
vidual variability).
Clinical observation in people with
AD reveals increasing variability of
performance with increasing levels
of dementia. The existing literature
supports this observation. Although
Thomas and Hageman5 found the
TUG to have reasonable test-retest
reliability in subjects in day care set-
tings who were considered to have
mild to moderate dementia (Mini-
Mental Status Examination [MMSE]
[SD]16.9 [7.3]), Tappen et al4
found the TUG to be impracticable
for use in subjects with moderate to
severe AD (MMSE9.3 [6.0]). Miller
et al,6 in a post hoc assessment of
performance on the 6MWT (as a
component of assessing test-retest
reliability of the Senior Fitness Test),
found that subjects who were cogni-
tively impaired showed greater vari-
ability than subjects who were cog-
nitively intact; they suggested that
the 6MWT is not reliable for use with
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impaired. The combined findings of
these studies4–6 and the previously
noted clinical observation suggest
that test-retest reliability of physical
and functional performance mea-
sures with individuals with AD may
be influenced by level of dementia.
The purposes of this research were:
(1) to determine test-retest reliability
of data for the TUG, the 6MWT, and
gait speed with individuals with AD;
(2) to determine MDC scores for
each of the outcome measures; and
(3) to identify performance differ-
ences between participant groups
stratified by level of dementia.
The existing literature guided the
choice of outcome measures for the
present study. We hypothesized that
the test-retest reliability of the clini-
cal tools would decrease with in-
creased level of dementia, such that
the measures would be reliable for
use with individuals with mild to
moderate AD, but not for use with
individuals with moderately severe
to severe AD. We also hypothesized
that, when stratified by level of de-
mentia, the participants who were
less cognitively impaired would per-
form better on the clinical tests com-
pared with the participants who
were more cognitively impaired.
Method
Participants and Procedure
This methodological study used a
prospective, nonexperimental, de-
scriptive research design. Guardian
informed consent was obtained for
all participants, with the exception
of one participant who signed her
own informed consent statement
with her family’s approval. When
possible, assent forms were signed
by participants in conjunction with
guardian informed consent. Four
sites providing care to individuals
with AD (2 inpatient programs and 2
day care programs) participated in
the study. The administrative contact
at each site aided in the recruitment
of participants. Inclusion criteria
were: probable diagnosis of AD,
medical stability, and ambulation
with or without an assistive device
or with handheld guiding assistance
of one person. Exclusion criteria
were: overt neuromuscular or mus-
culoskeletal problems, acute cardiac
or pulmonary conditions, and sur-
gery within the previous 6 months.
Background data were collected pri-
marily from the facility chart and in-
cluded: age, sex, living environment,
and use of an assistive device (classi-
fied as “none,” “use of a cane,” or
“use of a walker or rolling walker”)
or handheld guiding assistance for
ambulation. Personal information
(eg, vocation, avocations, family
members’ names, likes and dislikes)
was collected from the facility
record and staff. This information
proved useful in establishing rapport
with the participants. The primary
researcher (J.D.R.) administered the
MMSE to all participants. The pri-
mary researcher scored the Func-
tional Assessment Staging (FAST)
scale15–18 using a caregiver or staff
informant. The FAST scale has been
established as a reliable and valid as-
sessment tool for people with AD.19
The FAST instrument identifies 16
levels of functioning, separated into
7 stages (Tab. 1), and provided the
operational definitions for level of
AD in this study. The FAST scale was
used to stratify the participants into
2 groups based on level of dementia:
a mild to moderate AD group (FAST
scale score4 or 5) and a moderately
severe to severe AD group (FAST
scale score6 or 7).
Practical tips on interaction and
communication with individuals
with AD have been reported in the
literature. Every effort was made to
integrate these concepts into the
protocol for the present study to
maximize success of interactions, in-
cluding: creating a personal connec-
tion with the patient using personal
historical information; creating a
low-stress environment; using
friendly facial expressions, eye con-
tact, and a pleasant, but firm, voice;
one-step commands; and stating
meaningful goals.20–29 The progres-
sion of cuing for all tests also was
specific and based on the published
literature.30,31 Cuing began with ver-
bal instruction with a concurrent vi-
sual cue or gesture, followed by
modeling or demonstration, fol-
lowed by tactile guidance, and fi-
nally, if necessary, physical assis-
tance. Participants were given 10
seconds to respond to a cue before
the tester defaulted to a higher level
of cuing. A 7-level scale of assistance
developed by Beck et al31 for elderly
people with cognitive impairments
was used to classify the type of cuing
or assistance required for each par-
ticipant. If a participant required
handheld guiding assistance, every
effort was made to allow the partic-
ipant to drive the movement; how-
ever, if the participant stopped or
veered from the intended path of
movement, the researcher guided
the participant’s motion back on
task.
Two testing sessions for each partic-
ipant were performed on the same
day with a 30- to 60-minute rest pe-
riod separating testing sessions. Ev-
ery effort was made to keep all fac-
tors associated with the testing
sessions consistent (eg, general time
of day, staff member assisting with
testing, room or area in which test-
ing was performed). Participants
performed the TUG, the 6MWT, and
the test of gait speed.
The TUG32 is a test of the time re-
quired for an individual to stand up
from a chair with armrests, walk 3 m,
turn, walk back to the chair, and sit
down. In the present study, partici-
pants circled a small orange cone
placed at the 3-m mark. Participants
were instructed to “go as fast as you
safely can.” The stopwatch timing
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started when the participant’s bot-
tom left the chair and ended when
the bottom made contact with the
chair after the walk.
The 6MWT is the distance walked in
a period of 6 minutes. This test was
initially considered an endurance
measure33 but more recently has
been considered a broader measure
of mobility and function.34,35 The
6MWT was performed in long hall-
ways of the participating facilities.
Participants walked at a “comfort-
able pace,” were discouraged from
talking during the test, and were no-
tified of each passing minute. If par-
ticipants were distracted or stopped
walking, they were prompted to
“keep walking” and were advised of
the time remaining.
Self-selected gait speed was assessed
using the GAITRite walkway.* This
portable mat with embedded sensors
and companion software creates a
profile of temporal and spatial pa-
rameters of gait and is considered a
valid and reliable quantitative gait as-
sessment tool.36,37 Participants were
instructed to walk at a “comfortable”
pace for the length of the mat (4.57
m [15 ft]), and the walking path was
established such that acceleration
and deceleration did not occur on
the mat.
Testing took place at the participat-
ing facilities. Patients performed one
practice run of the TUG and one
practice pass on the GAITRite walk-
way. They did not perform a practice
run of the 6MWT, but were oriented
to the walking course. Each testing
session included 2 trials of the TUG,
2 passes at a comfortable pace on the
GAITRite mat, and 1 trial of the
6MWT. Tests were performed in
variable order to control for variabil-
ity of performance from first to last
test as a confounding factor. The or-
der of test administration was ran-
domized, determined by blind draw-
ing of test order from all possible
combinations for each participant.
The test order administration re-
mained constant from test session 1
to test session 2 for each participant.
Data Management and Analysis
We used SPSS 15.0 for Windows† for
data management and analysis. Level
of significance was predetermined to
be P.05 for all statistical analyses.
Descriptive statistics for compari-
sons of groups included independent-
samples t tests for parametric data
and chi square and Mann-Whitney
U tests for nonparametric data. All
descriptive comparisons between
groups were 2-tailed, as no assump-
tions of directionality were made.
Test-retest reliability of data for all
tests was assessed using the ICC
(model 2), which is appropriate for
methodological research.11,13 Reli-
ability of data obtained for the TUG
and gait speed was assessed using
the ICC (2,2), as mean scores from 2
* CIR Systems Inc, 60 Garlor Dr, Havertown,
PA 19083.
† SPSS Inc, 233 S Wacker Dr, Chicago, IL
60606-6412.
Table 1.
Functional Assessment Staging (FAST) Scale for People With Alzheimer Disease (AD)15,18
Stage Level of Functioning Clinical Diagnosis
1 No decrement “Normal” adult
2 Subjective deficit in word finding Normal-aged adult
3 Deficit in demanding employment settings Compatible with incipient AD
4 Assistance required in complex tasks (eg, handling finances, marketing,
planning dinner for guests)
Mild AD
5 Assistance required in choosing proper clothing Moderate AD
6a Assistance required in putting on clothing Moderately severe AD
6b Assistance required in bathing properly
6c Assistance required with the mechanics of toileting (eg, flushing, wiping)
6d Urinary incontinence
6e Fecal incontinence
7a Speech ability limited to approximately a half-dozen intelligible words Severe AD
7b Intelligible vocabulary limited to a single word
7c Ambulatory ability lost
7d Ability to sit up lost
7e Ability to smile lost
7f Ability to hold up head lost
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trials from each test session were
used in the calculations. Mean scores
are considered better estimates of
true scores and can increase reliabil-
ity estimates.13 For calculation of
test-retest reliability for the 6MWT,
the ICC (2,1) was used, as there was
only one test score from each ses-
sion. For each clinical test, the reli-
ability coefficient was calculated for
the entire sample and then sepa-
rately for the mild to moderate AD
group and the moderately severe to
severe AD group.
Independent-samples t tests were
used to determine differences in per-
formance on the clinical tests be-
tween the 2 groups. Comparisons
were made using the mean score of
all trials for each participant on the
given test (ie, mean of 4 TUG scores,
mean of 2 6MWT scores, and mean
of 4 gait speed measurements). One-
tailed tests were used to assess these
data, as there is evidence to suggest
that a decrease in speed occurs in
patients with dementia38–45; there-
fore, an assumption of directionality
was thought to be reasonable.
Standard errors of measurement and
MDC scores were calculated for the
TUG, the 6MWT, and gait speed.
Standard errors of measurement11
were calculated using the following
equation:
(1) SEM sd  1  r
In this equation, sd is the standard
deviation of the measure, and r is
the reliability coefficient (test-retest
reliability in the form of ICC for the
subject group). For repeated mea-
sures, the SEM was multiplied by the
square root of the number of
measurements.11
Minimal detectable change scores
were calculated for the TUG, 6MWT,
and gait speed data at the 90% con-
fidence interval. The formula used
for calculating MDC90
14,46 was:
(2) MDC90  SEM  1.65  2
In this equation, SEM was calculated
as described previously. The 1.65 in
the MDC90 equation represents the
z-score at the 90% confidence level.
The product of SEM multiplied by
1.65 is multiplied by the square root
of 2 to account for errors associated
with repeated measurements.
Results
Data were collected on a total of 53
participants. Two participants’ data
were eliminated from analysis be-
cause their dementia was later deter-
mined to be caused by factors other
than AD. One setting was not condu-
cive to the performance of the
6MWT, so that test was not per-
formed with participants in that set-
ting. On 2 occasions, individuals at
other settings declined to perform
the 6MWT. The Figure diagrams a
flowchart of participants, explaining
any differences between numbers of
participants tested and data used in
analysis of the results. The remaining
51 participants were stratified into
the mild to moderate AD group
(n20) and the moderately severe to
severe AD group (n31).
Descriptive statistics for the 51 sub-
jects are shown in Table 2. The 2
groups were similar in age, as deter-
mined by the independent-samples t
test, and similar in sex and living
environment (ie, home versus inpa-
tient), as determined by analysis of
frequencies using the chi-square test.
Mini-Mental Status Examination
scores also are presented in Table 2.
The MMSE scores of the 2 groups
were compared using the Mann-
Whitney U test, a nonparametric sta-
tistical analysis, given the ordinal na-
ture of the MMSE data. Given the
desire to compare the participants in
the present study with those in many
published studies that reported
MMSE findings using parametric sta-
tistics, mean scores and standard de-
viations are presented for both
groups as well. All participants were
consistent in their level of cuing
needs from test session 1 to test ses-
sion 2. The 2 groups were sig-
nificantly different in their level of
cuing needs, as evidenced by Mann-
Whitney U test analysis, with the par-
ticipants who were more cognitively
impaired requiring higher levels of
cuing than those who were less cog-
nitively impaired (Tab. 2). The use of
assistive devices (classified as
“none,” “use of a cane,” or “use of a
walker or rolling walker”) was simi-
lar between groups. More than 50%
of the participants of both groups
were ambulatory without assistive
devices. Six participants, all in the
moderately severe to severe AD
group, required handheld guiding as-
sistance for ambulation.
Intraclass correlation coefficients for
test-retest reliability were very high
for all outcome measures and for the
entire sample and each group (for
the TUG, ICC.985–.988, P.001;
for the 6MWT, ICC.982–.987,
P.001; and for gait speed,
ICC.973–.977, P.001).
There were statistically significant
differences between the mild to
moderate AD group and the moder-
ately severe to severe AD group on
TUG, 6MWT, and gait speed perfor-
mance. The participants who were
more cognitively impaired were
slower on the TUG and the test of
gait speed and walked shorter dis-
tances in the 6MWT compared with
the participants who were less cog-
nitively impaired (Tab. 3).
Repeated-measures SEMs were calcu-
lated for the TUG, the 6MWT, and
gait speed to provide a comparison
of individual variability of perfor-
mance across groups (Tab. 4). Al-
though there was little difference in
SEMs for the mild to moderate AD
group compared with the moder-
ately severe to severe AD group for
the 6MWT and gait speed (10% dif-
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ference), there was a substantial dif-
ference in SEMs for TUG scores be-
tween the 2 groups (100%
difference), with the participants
who were more cognitively impaired
showing greater variability of perfor-
mance compared with the partici-
pants who were less cognitively im-
paired. Table 4 also presents the
MDC90 values for the TUG, the
6MWT, and gait speed for all
participants.
Discussion
Our initial purpose was to determine
test-retest reliability of data for the
TUG, the 6MWT, and gait speed for
individuals with AD. All 3 outcome
measures were found to have excel-
lent test-retest reliability, well ex-
ceeding the r.90 threshold13 for
minimal acceptable reliability for a
clinical test and indicating that these
tests can be used clinically with good
confidence in their test-retest reli-
ability (ie, relative reliability). Test-
retest reliability was not influenced
by level of dementia, as was hypoth-
esized. Existing literature shows
mixed results for relative reliability
of these tools in people with AD and
dementia.
The TUG appears to be the most
widely studied of the tools. We cal-
culated an ICC of .987 for test-retest
reliability of TUG scores for all par-
ticipants. Tappen et al4 had such dif-
ficulty getting their subjects with
moderately severe to severe AD
(MMSE9.3 [6.0]) to perform the
TUG, that they had to modify the test
beyond recognition. Our partici-
pants in the moderately severe to
severe AD group had comparable
MMSE scores (10.2 [8.8]) and were
able to perform the test with excel-
lent relative reliability results. Rock-
wood et al7 reported an ICC of .56
Figure.
Flowchart of study participants. ADAlzheimer disease, MMSEMini-Mental Status Examination, 6MWTSix-Minute Walk Test,
TUGTimed “Up & Go” Test, GAITRitecomputerized walkway test of gait parameters.
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for test-retest reliability of TUG
scores in elderly individuals with
cognitive impairment, but their
methodology was fraught with diffi-
culties of working within the limita-
tions of retrospective data. A study
by Thomas and Hageman5 with a
small sample of individuals with
mild to moderate dementia (MMSE
16.9 [7.3]) revealed an ICC of .87 for
test-retest reliability of TUG scores,
and van Iersel et al10 examined test-
retest reliability in people with de-
mentia (MMSE19.1 [5.2]) and
found an ICC of .97 for the TUG.
These findings were more consistent
with the higher relative reliability
found in our study.
The 6MWT has not been widely used
in people with AD or dementia; how-
ever, Tappen et al4 reported that
their participants with AD who were
unable to perform the TUG were
able to perform the 6MWT. They did
not report test-retest reliability of the
6MWT scores, although the research
design was such that their ICCs of
.76 to .90 for intrarater reliability
(one rater observing 2 different ses-
sions) could potentially be inter-
preted as test-retest reliability. The
authors suggested that the 6MWT
may be the preferred test of physical
performance for people with AD.
We calculated an ICC of .987 for test-
retest reliability of 6MWT scores in
our study. Thomas and Hageman5
and van Iersel et al10 reported ICCs
of .92 and .77, respectively, for test-
retest reliability of measurements of
self-selected gait speed in people
with dementia. We calculated an ICC
of .977 for test-retest reliability of
gait speed measurements. Our find-
ings consistently showed higher test-
retest reliability on all 3 outcome
Table 2.











Age (y), XSD 80.718.77 81.059.48 80.488.43 t.223
df49
P.824
Sex (no. female [%]) 34 (66.7) 12 (60.0) 22 (70.7) 2.658
df1
P.417



















Sum of ranks: 675.50
Mean rank: 19.98
Sum of ranks: 599.50
Levels of assistance for elderly people with
cognitive impairment (level of cuing)
Mean rank: 19.05
Sum of ranks: 381.00
Mean rank: 30.48
Sum of ranks: 945.00
M-W U171.00
P.004*
a ADAlzheimer disease, MMSEMini-Mental Status Examination, tindependent-samples t test, dfdegrees of freedom, 2chi-square test of
independence, M-W UMann-Whitney U test of independent samples. Asterisk indicates statistically significant difference between dementia groups.
Table 3.
Performance Differences on Timed “Up & Go” Test, Six-Minute Walk Test, and Gait Speed Between Dementia Groups
Outcome Measure Dementia Group (n) XSD Independent-Samples t Test, t (df) P
Timed “Up & Go” Test (s) Mild to moderate AD (20) 19.959.81 1.876 (49) .0335*
Moderately severe to severe AD (31) 28.0117.49
Six-Minute Walk Test (ft) Mild to moderate AD (16) 938.78428.62 2.411 (31) .011*
Moderately severe to severe AD (17) 615.71338.34
Gait speed (cm/s) Mild to moderate AD (20) 66.0729.63 1.823 (49) .037*
Moderately severe to severe AD (31) 52.4323.58
a ADAlzheimer disease. Asterisk indicates statistically significant at P.05.
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measures compared with previous
research.
One factor that may have enhanced
performance on all clinical tests in
the present study was the careful use
and progression of cuing to facilitate
optimal performance. Although we
anticipated that performance consis-
tency from one trial to the next per-
haps would suffer with increasing
dementia, the steady and scripted
use of verbal and tactile cuing to
optimize performance was carefully
implemented; this may have consis-
tently facilitated the best perfor-
mance. Both Nordin et al8 and van
Iersel et al10 commented that the use
of cuing was the key to the success-
ful administration of the TUG in sub-
jects with cognitive impairment in
their recent reliability studies. In all
of the studies reviewed that ad-
dressed cuing, the authors either ex-
pressed simply a general statement
that cuing was allowed4,5,10 or re-
ported a dichotomy of cuing versus
no cuing.8
We believe that careful use of cuing
was an asset to consistency of per-
formance, contributing to the high
test-retest reliability findings for the
clinical tests in our study. Perhaps
our careful progression of cuing was
pivotal in the successful administra-
tion of the TUG in the moderately
severe to severe AD group, as Tap-
pen et al4 were unable to administer
the TUG to their subjects with com-
parable MMSE scores. Our partici-
pants’ cuing needs were rated and
documented (verbal cue/gesture,
modeling/demonstration, physical/
tactile prompt, progressive amounts
of physical guidance) and were con-
sistent from one testing session to
the next. Not surprisingly, partici-
pants with moderately severe to se-
vere AD required more substantive
prompting and guiding for perfor-
mance of the outcome measures
than those with mild to moderate
AD. Six of our 51 participants, all
from the moderately severe to severe
AD group, required handheld guid-
ing assistance of one person to com-
plete the outcome measures. With-
out the physical guidance of the
researcher, these participants would
not have been able to complete the
tests.
A recent publication by Hauer and
Oster47 reiterates that measuring
functional performance in people
with dementia is very complex and
cautions researchers that when we
provide external cues to patients,
perhaps we are measuring the reli-
ability and quality of the external cu-
ing (ie, the researcher’s perfor-
mance) as opposed to, or as well as,
the patients’ performance. In con-
trast, we contend that a consistent
progression of cuing to facilitate best
possible performance may be the op-
timal way to administer clinical tests
to people with AD or dementia. The
use of a consistent cuing paradigm,
in conjunction with following other
suggestions related to establishing
rapport and maintaining a nonthreat-
ening environment, may allow the
clinician or researcher to repeatedly
elicit the most favorable perfor-
mance from an individual with AD.
Our findings demonstrate that al-
though test-retest reliability (relative
reliability) for the clinical tests was
excellent, there was still a substantial
degree of variability of performance
for individual participants from one
test session to the next (absolute re-
liability). The SEM and MDC90 were
calculated to objectify these find-
ings. Because the SEM is based on an
assumption of normal distribution,
probabilities of the normal curve can
be applied to SEM values.11 Values
from Table 4 can be translated to
clinical performance using these
principles. For instance, there is a
68% probability that a repeated mea-
sure of the TUG will be within1.52
seconds (1 SEM) of the original score
for an individual with mild to mod-
erate AD and a 96% probability that a
repeated measure will be within
3.04 seconds (2 SEMs) of the original
score. For an individual with moder-
ately severe to severe AD, there is a
96% probability that a repeated mea-
sure of the TUG will be within6.06
seconds (2 SEMs) of the original
score. This could be useful informa-
tion when examining repeat perfor-
mances of individuals with AD on
the TUG. The dichotomy of demen-
tia levels is important in interpreting
clinical findings here, as a difference
in performance of approximately 4
to 5 seconds likely represents a
change beyond the expected vari-
ability in performance in a patient
Table 4.
Standard Error of Measurement (SEM) for Repeated Measures and Minimal Detectable Change Scores at the 90% Confidence










Severe AD Group (n31)
Timed “Up & Go” Test (s) 2.48 1.52 3.03 4.09
Six-Minute Walk Test (m) 20.28 (66.53 ft) 21.86 (71.72 ft) 19.57 (64.20 ft) 33.47 (109.8 ft)
Gait speed (cm/s) 5.72 6.07 5.48 9.44
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who is less cognitively impaired,
whereas this same change of approx-
imately 4 to 5 seconds would be
within the expected variability of
performance in a patient who is
more profoundly impaired.
The SEM findings for the TUG were
consistent with what was antici-
pated, with the group with a higher
level of dementia showing more vari-
ability of performance compared
with the group with a lower level of
dementia. However, this was not the
case with the 6MWT or gait speed
data. Differences in SEM between
groups for the 6MWT and gait speed
were small (10%), with the mild to
moderate AD group showing greater
variability of performance than the
moderately severe to severe AD
group. Given the small difference be-
tween groups, clinically, it seems
appropriate to use the SEM for all
individuals if calculating expected
performance on repeated measures
of the 6MWT and gait speed, irre-
spective of dementia level. Based on
these findings, there is a 96% proba-
bility that a repeated measure of the
6MWT will be within 40.5 m (133
ft) (2 SEMs) of the initial score. There
is a 96% probability that a repeated
measure of gait speed will be within
11.44 cm/s (2 SEMs) of the initial
measurement. These numbers give
wide ranges of performance that
would fall into the “expected” level
of variability on these tests, but still
could be clinically useful in the iden-
tification of “true” changes in indi-
viduals with AD.
The TUG is the only one of the out-
come measures we studied that has
previously been assessed for abso-
lute reliability. Nordin et al8 studied
the reliability of TUG scores with
participants stratified by cognitive
level. As in our study, they hypothe-
sized that increased cognitive impair-
ment would increase the variability
of TUG scores, but they found that
variability of performance was re-
lated not to cognitive level, but to
time to complete the TUG. Also like
our study, although their calculated
ICCs were high (.91 and .92 for in-
trarater and intertester reliability, re-
spectively), individual variability also
was high. Using logarithmically
transformed data, the authors cre-
ated a calculation for expected vari-
ability of TUG performance. This
method revealed a large degree of
variability or measurement error,
such that if an individual performed
the TUG in 20 seconds, the expected
range of performance on a repeated
measure could be between 13.2 and
30.3 seconds. If an individual’s per-
formance was 30 seconds, the ex-
pected range of a repeated measure
could be between 26.4 and 60.6 sec-
onds. Despite similarities in our gen-
eral study findings, we used substan-
tially different statistical mechanisms
to assess absolute reliability. Our
findings suggest that a smaller
change in performance on the TUG
(ie, 4.09 seconds) than proposed by
Nordin et al may represent a clini-
cally significant change. Again, it is
possible that our structured and con-
sistent use of cuing and our efforts to
maximize participant comfort and
minimize environmental stress were
effective in minimizing variability of
performance, resulting in more con-
sistency across trials.
Our final research goal was to iden-
tify performance differences be-
tween groups stratified by level of
dementia. There were significant dif-
ferences in performance between
the mild to moderate AD group and
the moderately severe to severe AD
group for the TUG, the 6MWT, and
gait speed. The findings of the
present study, within the context of
published data for the TUG,5,10,48,49
the 6MWT,4,48,50 and gait speed10,51
in individuals with dementia, clearly
represent a degradation of perfor-
mance with the progression of de-
mentia, and this performance de-
cline is beyond that seen with
normal aging. Admittedly, this is
piecing together data cross-section-
ally; a longitudinal study would be
helpful to confirm this observation
and would be a useful contribution
to the literature.
The present study indicates that the
TUG, the 6MWT, and gait speed
(using the GAITRite system) are reli-
able measures for use with individu-
als with AD. Recently, interpreting
change scores and identifying clini-
cally significant changes in perfor-
mance have become an explicit
focus of the physical therapy profes-
sion.14 Clinicians are encouraged to
understand how changes in scores
translate to clinical relevance. To
that end, this study presents MDC90
scores that provide meaningful cri-
teria for assessing performance
changes for people with AD on the
TUG, the 6MWT, and the gait speed
test (Tab. 4). Minimal detectable
change is the magnitude of change
that a measurement must demon-
strate to exceed the anticipated mea-
surement error and variability.14,46 If
a change in score occurs, in either
direction, that is greater than MDC90,
one can be 90% confident that the
difference was not due to measure-
ment error or patient variability. In
comparison with the SEM, this pro-
vides an even more conservative es-
timate of a change in score that is
clinically meaningful.
Rabheru52 recently published a call
for the expansion of the mechanism
for disease staging and milestones in
people with AD, stating that al-
though cognitive milestones are im-
portant, functional and behavioral
milestones may help to enhance the
general picture of the progression of
AD. The functional measures in the
present study could potentially be a
component of the staging process.
Van Iersel et al44 suggested that a
reasonable goal of research should
be to identify the minimal clinically
important changes in gait variables
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in the AD population. The present
study suggests that if a gait speed
change of greater than 9.44 cm/s is
detected in an individual with AD,
one can be 90% confident that this
represents a “true” change. This in-
formation could be helpful in inter-
preting clinical and research findings
related to performance changes in
gait speed. This study provides the
information to make similar judg-
ments with repeated TUG and
6MWT scores in individuals with AD.
Limitations
There were some limitations of this
study. The varied clinical presenta-
tion of participants bodes well for
the generalizability of the study find-
ings, but the limited geographical
(northern Virginia) and socioeco-
nomic (upper middle class) variabil-
ity of the group may threaten the
external validity of the study. The
logistics of using a single researcher
for data collection influenced sample
size and made it impossible to blind
the scorer to the dementia level of
the patient, which would be ideal in
this type of study.
Conclusions
This study demonstrated excellent
test-retest reliability for the TUG, the
6MWT, and gait speed in individuals
with AD. Significant differences
were found in performance of these
outcome measures between the mild
to moderate AD group and the mod-
erately severe to severe AD group,
with the participants who were less
cognitively impaired outperforming
those who were more cognitively
impaired. Despite very high ICCs for
test-retest reliability, there was nota-
ble individual variability in the per-
formance of these measures. Presen-
tation of SEM and MDC90, for each of
the measurement tools, provides cli-
nicians with meaningful thresholds
for identifying changes beyond those
expected from measurement error
and individual variability (ie, “true”
change) in individuals with AD. We
are confident that the consistent and
scripted use of cuing with partici-
pants was instrumental in the suc-
cessful administration of the out-
come measures and contributed to
consistency of participant perfor-
mance across trials. These findings
are relevant for both clinicians and
researchers. It is our hope that
MDC90 values for the TUG, the
6MWT, and gait speed presented
here will be helpful in monitoring
performance changes over time and
assessing the effectiveness of physi-
cal therapy and exercise interven-
tions in individuals with AD.
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